secukinumab
Marketed as COSENTYX.
FDA approval history
| FDA ID | Brand | Approval date | Manufacturer |
|---|---|---|---|
| BLA761349 | COSENTYX | 2023-10-06 | NOVARTIS PHARMS CORP |
| BLA125504 | COSENTYX | 2015-01-21 | NOVARTIS PHARMS CORP |
Manufacturers
NOVARTIS PHARMS CORP
Common denial patterns
- Step therapy requiring TNF-inhibitor before IL-17
- PASI score threshold not documented
- Indication-specific PA (PsA vs ankylosing spondylitis vs HS)
- Non-formulary in favor of IL-23 class
Specific notes
Brand: Cosentyx. IL-17A inhibitor. Expanded indications now include moderate-to-severe hidradenitis suppurativa (FDA approval October 2023). Self-administered subQ; loading then monthly maintenance.
Cosentyx Connect: https://www.cosentyx.com/cosentyx-connect
Frequently asked questions
Why does insurance commonly deny secukinumab?
Step therapy requiring TNF-inhibitor before IL-17; PASI score threshold not documented; Indication-specific PA (PsA vs ankylosing spondylitis vs HS); Non-formulary in favor of IL-23 class.
When was secukinumab FDA approved?
Earliest FDA approval on record: 2015-01-21.
What brand names are sold as secukinumab?
COSENTYX.
Is there a patient assistance program for secukinumab?
Yes — Cosentyx Connect at https://www.cosentyx.com/cosentyx-connect.
What's specific to secukinumab?
Brand: Cosentyx. IL-17A inhibitor. Expanded indications now include moderate-to-severe hidradenitis suppurativa (FDA approval October 2023). Self-administered subQ; loading then monthly maintenance.
Related
Sources
Appeal a secukinumab denial
Upload your denial — DenialHelp drafts a physician-ready appeal letter in five minutes with the right clinical guideline and federal regulation cited. $39 first-level, money back if we can't draft a strong appeal.
Get started →Contact: hello@denialhelp.com